Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Why Eli Lilly Stock Topped the Market Today
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
MM&M21h
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
BofA reiterates Eli Lilly buy rating, $997 target
BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a market capitalization of $706 billion and impressive revenue growth of 27.4% over the ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Greek Reporter17h
Greek News
Some of Athens's architectural landmarks were destroyed in the post-World War II years to make way for modern buildings that epitomized the rapid economic development of the country. Athens was the ...